寡转移和寡进展性肾细胞癌立体定向消融放疗的德尔菲共识——一项由欧洲泌尿外科学会认可的欧洲放射肿瘤学会研究
该ESTRO项目由欧洲泌尿外科学会认可,旨在通过德尔菲共识方法探索专家对寡转移和寡进展性肾细胞癌颅外转移灶立体定向消融放疗(SABR)的意见,以形成患者选择、治疗剂量和同期全身治疗的共识推荐。三轮问卷后,37个问题中仅8个达成共识,包括年龄和原发肾细胞癌组织学不限、寡进展患者可 ablative 治疗的上限为3个病灶、可同期使用免疫检查点抑制剂,以及骨和肾上腺寡转移为SABR首选。
要点
- SABR候选者不限年龄(25/25,100%)和原发肾细胞癌组织学(23/25,92%)。
- 寡进展患者可接受消融治疗的上限为3个病灶,且可同期使用免疫检查点抑制剂。
- 骨寡转移(20/25,80%)和肾上腺寡转移(22/25,88%)为SABR首选治疗方式。
核心结论
- 当前ESTRO德尔菲共识可能为SABR在寡转移性肾细胞癌中的应用提供有用方向,并突出持续争论的关键领域,或可指导未来研究以填补知识空白。
研究设计与样本
- 欧洲放射肿瘤学会(ESTRO)项目,由欧洲泌尿外科学会认可,采用德尔菲共识方法,由核心组准备问卷,10位知名专家组成小组审阅,向关键意见领袖临床医生发送三轮问卷。
主要发现
- 第三轮结束时,参与者在37个问题中的8个达成共识。
- 专家小组同意SABR候选者不限年龄(25/25,100%)和原发肾细胞癌组织学(23/25,92%)。
- 专家小组同意寡进展患者可接受消融治疗的上限为3个病灶,并同意同期使用免疫检查点抑制剂。
- SABR被指示为肾细胞癌骨寡转移(20/25,80%)和肾上腺寡转移(22/25,88%)的首选治疗方式。
- 关于合适的分割方案未达成共识或主要一致,但多数投票(54%-58%)保留隔日方案作为所有研究部位的最佳选择。
关键数值与推荐
- SABR候选者不限年龄:25/25(100%)同意。
- SABR候选者不限原发肾细胞癌组织学:23/25(92%)同意。
- 寡进展患者可接受消融治疗的上限为3个病灶:达成共识。
- 可同期使用免疫检查点抑制剂:达成共识。
- 骨寡转移为SABR首选治疗方式:20/25(80%)同意;肾上腺寡转移:22/25(88%)同意。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于合适的分割方案未达成共识或主要一致,但多数投票(54%-58%)保留隔日方案作为所有研究部位的最佳选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on the management of patients with oligometastatic and oligoprogressive renal cell carcinoma by means of stereotactic ablative radiotherapy (SABR) on extracranial metastases, with the aim of developing consensus recommendations for patient selection, treatment doses, and concurrent systemic therapy. A questionnaire on SABR in oligometastatic renal cell carcinoma was prepared by a core group and reviewed by a panel of ten prominent experts in the field. The Delphi consensus methodology was applied, sending three rounds of questionnaires to clinicians identified as key opinion leaders in the field. At the end of the third round, participants were able to find consensus on eight of the 37 questions. Specifically, panellists agreed to apply no restrictions regarding age (25 [100%) of 25) and primary renal cell carcinoma histology (23 [92%] of 25) for SABR candidates, on the upper threshold of three lesions to offer ablative treatment in patients with oligoprogression, and on the concomitant administration of immune checkpoint inhibitor. SABR was indicated as the treatment modality of choice for renal cell carcinoma bone oligometatasis (20 [80%] of 25) and for adrenal oligometastases 22 (88%). No consensus or major agreement was reached regarding the appropriate schedule, but the majority of the poll (54%-58%) retained the every-other-day schedule as the optimal choice for all the investigated sites. The current ESTRO Delphi consensus might provide useful direction for the application of SABR in oligometastatic renal cell carcinoma and highlight the key areas of ongoing debate, perhaps directing future research efforts to close knowledge gaps.
引用
- Marvaso G, Jereczek-Fossa BA, Zaffaroni M, et al. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. Lancet Oncol. 2024. PMID: 38697165. doi:10.1016/S1470-2045(24)00023-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。